title: Elevated preoperative serum ICTP is a prognostic factor for overall and disease-free survival in breast cancer.
abstract: The aim of this study was to evaluate the prognostic value of preoperative concentrations of the serum markers of type I collagen synthesis (PINP, PICP) and degradation (ICTP) in breast cancer. One hundred and eighty-four breast cancer patients without advanced disease were enrolled. Preoperative serum markers of type I collagen were assessed with specific radioimmunoassays. Elevated preoperative serum concentrations of ICTP (>4.9 microg/l) correlated statistically significantly with a poor prognosis for the breast cancer (P=0.0004) and shorter disease-free survival (P=0.02), and multivariate regression analysis likewise showed an elevated ICTP concentration (P=0.008), high grade (P=0.03) and high pathological stage (P=0.02) to be risk factors for poor survival. Sixty-five out of the 184 patients developed metastatic disease during the follow-up. The median follow-up time was 62 months (range 6-111 months). High ICTP (P=0.02) and large numbers of metastatic nodules (P=0.002) were prognostic factors for shorter disease-free survival in multivariate regression analysis. PINP and PICP had no significant prognostic value with respect to either overall or disease-free survival in this analysis. Our results indicate that preoperatively elevated serum ICTP is a prognostic factor in breast cancer, the measurement of which should improve the accuracy of predictions of the clinical outcome.
authors.affiliation: Department of Oncology, Kuopio University Hospital, Kuopio, Finland.
authors.forename: Riitta
authors.initials: R
authors.lastname: Keskikuru
authors.forename: Risto
authors.initials: R
authors.lastname: Bloigu
authors.forename: Juha
authors.initials: J
authors.lastname: Risteli
authors.forename: Vesa
authors.initials: V
authors.lastname: Kataja
authors.forename: Arja
authors.initials: A
authors.lastname: Jukkola
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000401:mortality / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000097:blood / Q000401:mortality / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000097:blood / Q000401:mortality / Q000473:pathology; D018275:Carcinoma, Lobular / Q000097:blood / Q000401:mortality / Q000473:pathology; D016022:Case-Control Studies; D003094:Collagen / Q000097:blood*; D024042:Collagen Type I; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000097:blood*; D011379:Prognosis; D011446:Prospective Studies; D011863:Radioimmunoassay; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D024042:Collagen Type I; D010455:Peptides; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C052929:collagen type I trimeric cross-linked peptide; D003094:Collagen